Evogene Ltd., 2026-02-19
An SEC Form D private-offering notice from Rehovot, a $3,384,616 filer-stated offering target in Biotech. Filed 2026-02-19. The source filing is one click away. For companies that filed this week, open the live feed.
What this filing says
Evogene is a Rehovot, Israel based public computational biology company (Nasdaq/TASE: EVGN) using AI driven small molecule design for pharmaceuticals and crop protection.
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.
Other Form D filings from the same week
each with its own page and its own EDGAR source- ILIAD BIOTECHNOLOGIES, INC., 2026-02-20, $115.5M, Weston, FL
- Vitazi.AI, Inc., 2026-02-20, $3M, Santa Fe, NM
- Akava Therapeutics Inc., 2026-02-19, $15M, Winnetka, IL
- Verra Therapeutics, Inc., 2026-02-18, $450K, Lansing, NY
- Accretion Therapeutics, Inc., 2026-02-17, $1M, Lincolnshire, IL
- Treysta Medical Technologies Inc., 2026-02-17, $300K, Gainesille, FL
The Monday digest, free
A summary of who raised money last week: the ones worth a call first, then every company that filed, by state and sector. One email, Monday mornings. No spam, unsubscribe anytime.
By subscribing you agree to our Terms and Privacy Policy.